Tianjin Medical University Cancer Institute & Hospital (TMUCIH) is a premier cancer treatment and research center located in Tianjin, China. Established in 1861, TMUCIH has evolved into a leading institution renowned for its comprehensive cancer care, cutting-edge research, and advanced medical education. The hospital offers a full spectrum of oncology services, including diagnostics, surgical treatments, chemotherapy, radiation therapy, and immunotherapy, supported by state-of-the-art facilities and technology. TMUCIH is dedicated to pioneering research in cancer biology, treatment modalities, and preventive oncology, contributing significantly to global cancer research. As an affiliated hospital of Tianjin Medical University, it plays a crucial role in training the next generation of healthcare professionals, fostering an environment of academic excellence and innovation. With a steadfast commitment to patient-centered care, TMUCIH strives to provide the highest quality medical services, improve patient outcomes, and enhance the well-being of the communities it serves.

Tianjin Medical University Cancer Institute & Hospital (TMUCIH) is renowned for its comprehensive range of specialties in oncology, making it a leading institution for cancer treatment and research in China. The hospital excels in medical oncology, offering advanced chemotherapy, targeted therapy, and immunotherapy to treat various types of cancer. Its surgical oncology department is distinguished for performing complex cancer surgeries, including minimally invasive and robotic-assisted procedures. TMUCIH's radiation oncology division utilizes cutting-edge technologies such as intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), and brachytherapy to provide precise and effective cancer treatment. The hospital is also a leader in hematology, treating blood cancers like leukemia, lymphoma, and multiple myeloma with the latest therapeutic approaches. Additionally, TMUCIH offers specialized care in pediatric oncology, addressing the unique needs of children with cancer. Its comprehensive cancer care includes support services such as palliative care, pain management, and psychological support, ensuring holistic treatment for patients. With a strong focus on research and innovation, TMUCIH continuously advances in cancer diagnostics and treatment, reinforcing its status as a top-tier cancer care institution.

Vision: Tianjin Medical University Cancer Institute & Hospital (TMUCIH) aspires to be a global leader in cancer care, research, and education. Our vision is to set the standard for excellence in oncology, providing innovative, compassionate, and patient-centered care. We aim to advance the understanding and treatment of cancer through groundbreaking research and to educate and inspire the next generation of healthcare professionals dedicated to eradicating this disease.

Mission: Our mission at TMUCIH is to deliver the highest quality cancer care, tailored to the unique needs of each patient, through cutting-edge treatments and a multidisciplinary approach. We are committed to fostering a collaborative environment that encourages innovation and excellence in clinical practice, research, and education. By integrating advanced medical technology, evidence-based practices, and compassionate care, we strive to improve patient outcomes, enhance the quality of life for our patients, and contribute to the global fight against cancer. Through our dedication to these principles, we seek to make a meaningful impact on the lives of our patients and the broader medical community.

Tianjin Medical University Cancer Institute & Hospital (TMUCIH) has earned numerous awards and recognitions for its outstanding contributions to cancer care, research, and medical education. The hospital is frequently ranked among the top cancer treatment centers in China, reflecting its excellence in clinical outcomes and patient care. It has received prestigious accolades such as the "National Clinical Key Specialty Construction Project" designation from the Ministry of Health, recognizing its advanced capabilities in oncology. TMUCIH has also been accredited by the Joint Commission International (JCI), a testament to its adherence to the highest global standards in healthcare quality and patient safety. The hospital's research teams have been honored with multiple national and provincial science and technology awards for their groundbreaking work in cancer biology, treatment innovations, and preventive oncology. Additionally, TMUCIH has been commended for its contributions to medical education and training, earning accolades for its role in developing future leaders in oncology. These awards and recognitions underscore TMUCIH's commitment to excellence, innovation, and compassionate care, solidifying its reputation as a leading institution in the fight against cancer.